Marker Therapeutics (MRKR) Non-Current Deferred Tax Liability (2019)

Marker Therapeutics (MRKR) reported Non-Current Deferred Tax Liability of $106000.0 for Q4 2019.

Marker Therapeutics (MRKR) Non-Current Deferred Tax Liability (2019) Analysis & Trends

Marker Therapeutics (MRKR) has 1 years of Non-Current Deferred Tax Liability data on file, last reported at $106000.0 in Q4 2019.

Non-Current Deferred Tax Liability for Q4 2019 came in at $106000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $106000.0 (changed N/A YoY), and the FY2019 annual result was $106000.0, changed N/A from the prior year.
Non-Current Deferred Tax Liability steadied at $106000.0 in Q4 2019 per MRKR's latest filing.
Over five years, Non-Current Deferred Tax Liability peaked at $106000.0 in Q4 2019 and troughed at $106000.0 in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn
9	Abivax	95.45 Bn	95.45 Bn	-
10	Marker Therapeutics	27.04 Mn	27.04 Mn	-

Download Data

Date	Value
Dec 31, 2019	106,000.00
Dec 31, 2019	106,000.00